Study of TAVO103A in Healthy Volunteers

NCT05313152 | Completed Phase 1 DMC FDA Drug

• 1 other identifier: 59870002
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase 1, single ascending dose study designed to investigate TAVO103A, administered as an IV infusion up to 60 minutes in length to healthy adult subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO103A.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (5)

• The severity of adverse effects according to the CTCAE Guidance for Industry, Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials [Time Frame: Day 1 through Day 196]

  To investigate the safety and tolerability of TAVO103A in healthy volunteers. The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials will be graded according to the National Cancer Institute's Common Terminology Criteria for AEs, Version 5.0. Which will have a minimum value of Grade 1, or mild, and a maximum value of Grade 4, or Potentially Life Threatening.

  196 days

• Changes in vital signs including oral temperature or tympanic temperature (C°) [Time Frame: Day 1 through Day 196]

  To investigate the safety and tolerability of TAVO103A in healthy volunteers.

  196 days

• Changes in vital signs including respiratory rate (breaths per minute) [Time Frame: Day 1 through Day 196]

  To investigate the safety and tolerability of TAVO103A in healthy volunteers.

  196 days

• Changes in vital signs including systolic and diastolic blood pressure (mmHg) [Time Frame: Day 1 through Day 196]

  To investigate the safety and tolerability of TAVO103A in healthy volunteers.

  196 days

• Changes in vital signs including pulse rate (beats per minute) [Time Frame: Day 1 through Day 196]

  To investigate the safety and tolerability of TAVO103A in healthy volunteers.

  196 days

Secondary Outcomes (10)

• Immunogenicity of TAVO103A [Time Frame: Day 1 through Day 196]

  196 days

• Cmax (Maximum observed serum concentration ) [Time Frame: Day 1 through Day 196]

  196 days

• tmax (time that Cmax was observed) [Time Frame: Day 1 through Day 196]

  196 days

• AUC-last (Area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration; calculated using the linear/log trapezoid rule) [Time Frame: Day 1 through Day 196]

  196 days

• AUC-inf (Area under the serum concentration-time curve from time 0 extrapolated to infinity) [Time Frame: Day 1 through Day 196]

  196 days

Study Arms (4)

TAVO103A Low Dose

EXPERIMENTAL

TAVO103A: TAVO103A single ascending dose IV infusion.

Drug: TAVO103A

TAVO10A Medium Dose

EXPERIMENTAL

TAVO103A: TAVO103A single ascending dose IV infusion.

Drug: TAVO103A

TAVO103A High Dose

EXPERIMENTAL

TAVO103A: TAVO103A single ascending dose IV infusion.

Drug: TAVO103A

Placebo

PLACEBO COMPARATOR

Placebo single ascending dose IV infusion.

Other: Placebo

Interventions

TAVO103A DRUG

TAVO103A single ascending dose IV infusion.

TAVO103A High Dose; TAVO103A Low Dose; TAVO10A Medium Dose

Placebo OTHER

Placebo single ascending dose IV infusion.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females ≥ 18 and ≤ 65 years of age, inclusive.
• Subjects must have a body weight range of ≥ 50 kg and ≤ 100 kg, inclusive, and a BMI ≥ 18.0 and ≤ 30.0 kg/m2, inclusive.
• Subjects must be healthy based on clinical laboratory tests performed at Screening and Day -1.
• Females of childbearing potential who are sexually active with a male partner must agree to use a highly effective method of contraception from screening through the end of the study.
• Males who are sexually active and nonsterile, and whose partners are females of childbearing potential must agree to use condoms from screening through the end of the study.
• Males must agree to not donate sperm from screening through the end of the study.
• Subjects must be able to communicate effectively with the study personnel.
• Subjects must be nonsmokers, defined as having abstained from tobacco- or nicotine-containing products in the 6 months prior to Screening.
• Subjects will be considered eligible according to the following tuberculosis screening criteria's.
• Subjects must sign an informed consent form.

You may not qualify if:

• Positive pregnancy test or is lactating at any time during the study.
• History or presence of conditions which, in the judgment of the investigator, are known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
• History or presence of conditions that may place the subject at increased risk as determined by the investigator.
• Subject currently has or has had a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the subject.
• Subject has a QT corrected according to Fridericia's formula (QTcF) interval \> 450 msec (males) or \> 470 msec (for females), has a complete left or right bundle branch block, or has a history or current evidence of additional risk factors for Torsades de Pointes.
• History of surgery or major trauma within 16 weeks of Screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study, or within 17 weeks after the last dose of study drug administration.
• Subject plans to undergo non-major elective surgery within 4 weeks prior to study drug administration through EOS.
• Subject has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of TAVO103A and its excipients used in this study.
• History of alcohol abuse, illicit drug use, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of Screening.
• Use of prescription medications within 14 days or any drugs that induce or inhibit study drug-specific cytochrome 450(s) within 14 days or 5 half-lives (if known), whichever is longer, prior to administration of the study drug. By exception, prescription drugs, such as hormonal birth control or hormone replacement therapy, will be permitted.
• Use of OTC drugs (including herbal preparations) within 7 days or 5 half-lives (if known), whichever is longer, prior to administration of the study drug. Common OTC drugs are acceptable with investigator approval.
• Has received a vaccination within 30 days prior to administration of the study drug
• Has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's PK, PD, or biological activity (if known), whichever is longer, prior to administration of the study drug in this study or is currently participating in another clinical study.
• Significant blood loss (\> 450 mL) or has donated 1 or more units of blood or plasma within 6 weeks prior to study participation.
• Strenuous activity within 48 hours prior to CRU admission.

Sponsors & Collaborators

• Tavotek Biotherapeutics: lead

Study Sites (1)

ICON

Salt Lake City, Utah, 84124, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 28, 2022
• First Posted: April 6, 2022
• Study Start: April 5, 2022
• Primary Completion: April 26, 2023
• Study Completion: June 8, 2023
• Last Updated: December 12, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)